GENERAL10 Sept 2026
Molbio Diagnostics share price hits 20% upper circuit, jumps 87% from IPO price | Stock Market News
Molbio Diagnostics shares rose 20% on 10 September 2026, touching an all-time high of ₹1,509.70, roughly 87% above its initial public offering (IPO) price of ₹807. The company posted a ₹52.74 crore profit for Q1 FY27, helped by higher Truenat test-kit sales, compared with a loss a year ago. If you hold these shares, stay disciplined instead of chasing the rally.
Key Statutory Highlights
- Molbio Diagnostics shares were locked in a 20% upper circuit on 10 September 2026 and touched an all-time high of ₹1,509.70 on the BSE.
- The stock has gained nearly 87% from its IPO price of ₹807 per share since listing on 17 August 2026.
- Truenat test-kit volumes jumped to 62.4 lakh units in Q1 FY27 from 7.9 lakh units in the same quarter last year.
Actionable Advice for Taxpayers / Founders:If you are thinking of buying Molbio shares after this sharp run-up, check your own risk appetite and holding period first, and speak to a registered investment adviser before acting. A fast post-listing rally can also fall quickly.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: